Immune suppressive activities exerted by regulatory T-cell subsets have several specific functions, including self-tolerance and regulation of adaptive immune reactions, and their dysfunction can lead to autoimmune diseases and contribute to AIDS and cancer. Two functionally distinct regulatory T-cell subsets are currently identified in peripheral tissues: thymus-developed natural T regulatory cells (nTregs) controlling self-tolerance and antiinflammatory IL-10-secreting type 1 regulatory T cells (Tr1) derived from Ag-stimulated T cells, which regulate inflammation-dependent adaptive immunity and minimize immunopathology. We establish herein that cell contact-mediated nTreg regulatory function is inhibited by inflammation, especially in the presence of the complement C3b receptor (CD46). Instead, as with other T-cell subsets, the latter inflammatory conditions of stimulation skew nTreg differentiation to Tr1 cells secreting IL-10, an effect potentiated by IFN-α. The clinical relevance of these findings was verified in a study of 152 lupus patients, in which we showed that lupus nTreg dysfunction is not due to intrinsic defects but is rather induced by C3b stimulation of CD46 and IFN-α and that these immune components of inflammation are directly associated with active lupus. These results provide a rationale for using anti-IFN-α Ab immunotherapy in lupus patients. autoimmunity | lupus pathogenesis | regulatory T cell functional diversity | inflammation-driven regulatory T cell regulation | anti-IFNα immune therapy
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autoimmunity | lupus pathogenesis | regulatory T cell functional diversity | inflammation-driven regulatory T cell regulation | anti-IFNα immune therapy I nflammation triggers adaptive immunity, which is initiated by conventional helper CD4 T cells (Tconv). The cytokines released by Tconv (CD4 + CD127 + ) drive adaptive responses by both cellular (cytotoxic) or humoral (Ab dependent) mechanisms. Two T-cell immunosuppressive functions exerted by regulatory T cells control adaptive immune reactions to prevent immunopathology in peripheral tissues (1) (2) (3) (4) . One of these is the natural T regulatory cells (nTregs) characterized by their CD4 + CD25
high CD127
low/neg FoxP3 + phenotype (5, 6) , which control autoreactive cells, thereby allowing for self-tolerance (1) (2) (3) . The second is type 1 regulatory T cells (Tr1), defined by their secretion of IL-10, lack of IL-4 (7), and down-regulation of adaptive immunity to pathogens (8) , minimizing tissue damage from immune reactions (9) .
An impairment of self-tolerance is a hallmark of autoimmunity and particularly of systemic lupus erythematosus (SLE). This potentially fatal disease (10) is characterized by episodes of exacerbated inflammatory reactions that affect multiple organs. Dysfunction of nTregs (11) is critically involved in lupus pathogenesis, but the origin of the defect is unclear and controversial (Table S1 ). Two components of SLE inflammation are a dysregulation of complement (C′) activation pathways (12) and overproduction of circulating IFN-α (13) . Consequently, we hypothesized that these components of inflammation impair nTreg function, and to address this hypothesis we investigated the physiologic characteristics of normal nTregs, including their regulatory function in response to immune stimulations under noninflammatory (steadystate) and inflammatory conditions, especially those observed in SLE.
Results
Physiological Characteristics of nTreg Cells. Immune activation, proliferation, and functional differentiation of nTregs purified from peripheral blood mononuclear cells (PBMCs) derived from healthy donors (HD) (Fig. S1 ) vary according to their microenvironment. In peripheral tissues nTreg stromal microenvironment can be inflammatory or not (steady state), according to the immune components of the tissue, such as C′ proteins, IFN-α, dendritic cell macrophages, natural killer cells, and other blood cells. nTreg stimulation under steady state. nTregs were stimulated with anti-CD3 mAbs in the presence of irradiated CD3-depleted PBMCs (ΔCD3-feeder) (14) . Under steady state, they exhibit anergic characteristics with loss of activation and lack of proliferation as assessed by CD25 and carboxyfluorescein succinimidyl ester (CFSE) markers ( Fig. 1 A and B) , because of their incapacity to synthesize IL-2 (15, 16) . However, cocultured with Tconv cells, nTregs were activated, proliferated, and, as measured by the current nTreg suppressive assay (14, 17) , exerted their cell contact-mediated regulatory activity ( Fig. 1 A-C) . Indeed, proliferation of CD3-stimulated Tconv-responder cells was inhibited by addition of nTregs in an nTreg/responder cell ratio dependency. However, when assays were performed in transwell plates to prevent nTreg-Tconv cell contact, Tconv-responder cell proliferation was not inhibited (Fig. 1D1) . Additionally, anti-IL-10/ anti-IL-10 receptor Abs added to the coculture failed to block nTreg suppressive activity (Fig. 1D2) , whereas supernatant of CD3-stimulated nTreg-Tconv coculture harbored minimal IL-10 levels (Fig. S2) . These experiments showed that, under steady state, nTregs exert their suppressive function by cell-cell contact and not by soluble factors. nTreg stimulation under inflammation conditions. To mimic T-cell stimulation under inflammatory conditions in addition to anti-CD3 mAbs, we used anti-CD28 mAbs as a substitute for mature dendritic cell B7 costimulation, known to induce IL-2 production during T-cell activation (18, 19) . CD3/CD28-stimulated nTregs were not activated and did not proliferate when cultured with ΔCD3-feeder ( Fig. 1 A and B) . By contrast, nTregs after either CD3/CD28 stimulation in coculture with Tconv supplying IL-2 ( Fig. 1 A and B) or CD3 stimulation in the presence of exogenous IL-2 markedly increased their activation state and their proliferation ( Fig. 1 A and B) . However, in both stimulation conditions, nTreg suppressive effects were inhibited (Fig. 1C) . The inhibition level correlated with the magnitude of CD28 costimulation ( Fig. 1E1 ) and was IL-2 dose-dependent (Fig. 1E2) . Considering that CD3/CD28-stimulated Tconv cells release IL-2 in an anti-CD28 Ab-dependent manner (Fig. 1E3) , we assumed that the inhibition of cell contact nTreg suppressive function was mediated by IL-2. This assumption was further experimentally supported, given that nTregs recovered their cell contact suppressive activity in the presence of anti-IL-2 Abs (Fig. 1E1) . These experimental data show the critical implication of IL-2 in the nTreg suppressive function, stressing particularly the dual effect of this cytokine. Whereas minimal amounts of IL-2 are required for nTreg cell contact suppression, higher amounts inhibit this function in a dose-dependent manner.
Extending the pioneering study on IL-2-induced abolition of murine nTreg function by Takahashi et al. (15) , these experiments established that, under stimulatory conditions mimicking inflammation-induced adaptive reactions associated with IL-2 production, human nTreg physiology and their functional capacity differ from the steady state. Inflammation-dependent variations included (i) IL-2-induced nTreg proliferation, which may ensure their homeostatic self-renewal as reported (20) , and (ii) IL-2 dosedependent inhibition of nTreg cell contact-mediated regulatory function during adaptive immunity (Fig. 1E2) .
Impact on nTreg Physiology of Innate Immune Components Expressed
During Active Lupus. As mentioned above, the dysregulation of C′ activation (12) and circulating IFN-α (13) are two major innate immunity components described in active lupus. Effect of complement C3b. The cleavage of C3 protein during activation of C′ pathways releases the C3b fragment, a natural ligand of the C′ regulatory receptor CD46 in T cells. The impact of CD46 costimulation on CD4 T-cell subsets was previously investigated by Kemper et al. (21) . The authors reported that the CD4 T-cell costimulation with anti-CD46 Abs or C3b dimers in the presence of IL-2 skewed the differentiation of these cells to IL-10-secreting Tr1 cells (21, 22) . We confirmed that additional costimulation of CD4 cells with either anti-CD46 Abs or C3b dimers skewed CD4 cell differentiation to IL-10-secreting Tr1 cells (Fig. S3) .
In the present study we investigated the impact of CD46 costimulation on CD3 and CD3/CD28-stimulated nTregs. After CD3/CD46 Ab stimulation, nTregs cultured alone were not activated and did not proliferate. However, cocultured with Tconv cells supplying IL-2, nTregs were activated and proliferated ( Fig. 2 A1 and A2), but their cell contact suppressive function, as tested by the nTreg suppressive assay, was abrogated (≥98%) (Fig. 2A3) . Fig. 2 A1 and A2 also shows that, after CD3/CD28/CD46 stimulation, the slight activation and the proliferation of nTregs cultured alone were enhanced by coculture with Tconv cells. Furthermore, CD3/CD28/CD46-stimulated nTregs lost their cell contact suppressive function as tested by the nTreg assay (Fig. 2A3) .
Effects of IFN-α. In this study the IFN-α effects on nTreg and Tconv cells was investigated after CD3/CD28 stimulation with or without additional CD46 costimulation. Because it is well established that immune stimulation of nTreg required IL-2 (23), the IFN-α effects on these cells were studied either in presence of Tconv cells or of exogenous IL-2. IFN-α inhibited, in a dose-dependent manner, activation and proliferation of CD3/CD28-stimulated nTregs cocultured with Tconv, as well as of CD3/CD28-stimulated Tconv ( Fig. 2 B1 and B2) . Furthermore, after CD3/CD28/IL-2 stimulation of these CD4 cell subsets, IFN-α significantly increased cell death (Fig. 2B3) . IFN-α effects collectively resulted in a reduced cell number of nTreg and Tconv subsets. As reported for other T-cell subsets (24) , after CD3/CD28/IL2 stimulation, IFN-α induced the release by nTregs and Tconv cells of IL-10. This effect was markedly enhanced by additional CD46 costimulation (Fig. 2C ). Of note, the absence of the cell contact regulatory activity of nTreg after CD3/CD28±CD46 stimulation was still observed in the presence of IFN-α (Fig. S4) . per well), pbαCD3 mAb (0.5 μg/mL), sαCD28 mAb (1 μg/mL), and increasing concentrations of IFN-α (0.1-100 ng/mL) for 4 d. In a parallel experiment, Tconv CFSE were cultured alone under the same stimulation conditions as those described above. (B1) T-cell activation status (CD25 MFI) on both CFSE-labeled T-cell subsets, measured by flow cytometry, and (B2) T-cell proliferation measured by CFSE dilution assay: IFN-α dose-effect inhibition (mean % ± SD) (n = 3). (B3) Apoptosis of 6 d-cultured nTregs and Tconv (2 × 10 5 per well) stimulated with pbαCD3 mAb (0.5 μg/mL) in presence of sαCD28 mAb (4 μg/mL), IL-2 (100 IU/mL), without or with IFN-α (10 ng/mL) was evaluated by 7-amino-actinomycin D staining (35) : mean % (apoptotic cells + apoptotic bodies/debris) ± SD of four experiments. (C) IL-10 production by Tr1 differentiated nTregs compared with that of Tconv. nTregs and Tconv (2 × 10 5 per well) were stimulated with pbαCD3 mAb (0.5 μg/mL) in presence of sαCD28 mAb (4 μg/mL), IL-2 (100 IU/mL), without or with IFN-α (10 ng/mL). Where indicated, additional costimulatory signals were provided by pbαCD46 mAb (10 μg/mL). (C1) IL-10 mRNA levels measured by RT-PCR in the 36 h-cultured T-cell subsets (mean ± SD) (n = 3). (C2) IL-10 levels quantified by ELISA in the 4 d-culture supernatant of nTregs and Tconv stimulated as indicated (mean ± SD) (n = 3).
whether nTregs differentiate to IL-10-secreting Tr1 under inflammatory conditions, as reported for helper Tconv (8) . This was experimentally confirmed using a transwell plate assay and an appropriate concentration of cells (Fig. 3A1) . nTregs, like Tconv, after CD3/CD28/+IL-2/±CD46 stimulation (inflammatory context) but not CD3 stimulation (steady-state context), released IL-10 ( Fig. 3A2 ) at suppression levels in the range of nanograms per milliliter (Fig. S5 ) and also inhibited responder T-cell proliferation through soluble factors (Fig. 3A3) . Thus, under stimulating conditions mimicking inflammation, which abolished their cell contact-mediated suppressive capacity (Figs. 1C and  2A3) , nTregs differentiate to IL-10-secreting Tr1 and down-regulate immune-stimulated T-cell proliferation (Fig. 3A3) . Importantly, after a 3-d resting period at room temperature, Tr1-differentiated nTregs reverted their IL-10-dependent functional capacity to their original cell-cell contact-mediated suppressive characteristics, when nTreg-Tconv CFSE cocultures were performed under steady state. Indeed, Fig. 3B shows that IL-10- ; (C3) mean % (apoptotic cells + apoptotic bodies/debris) ± SD of three experiments. *P < 0.05; **P < 0.005; ***P < 0.001; ns, P > 0.05. producing cells differentiated from CD3/CD28/IL-2±CD46-stimulated nTregs (Fig. 3B1) , recovered their initial cell contactmediated suppressive function to the same extent as that of freshly isolated nTregs from which they originated (Fig. 3B2) . Of note, the nTreg-Tconv CFSE coculture supernatants in these experiments harbored background levels of IL-10 (Fig. S6) .
Clinical Relevance in Lupus Patients. The clinical relevance of these data was assessed in a study of lupus patients (Table S2) . As reported (25) , in the line with IFN-α effects on CD4 cells, active (n = 49) compared with inactive lupus patients (n = 103) or HD exhibited lymphopenia (P = 0.002 and P < 0.001, respectively), a lower blood CD4 T-cell percentage, and among them, a reduced number of CD25 bright nTregs (Fig. 4A) . Remarkably, removed from their in vivo inflammatory environment, sorted nTregs from active and inactive lupus patients, when CD3-stimulated under steady state, exerted a normal cell contact suppressive function, like HD nTregs (Fig. 4B1) . This function was abrogated by CD3/CD28/CD46 stimulation (Fig. 4B2) ; instead, the latter stimulation, mimicking SLE inflammatory conditions, skewed lupus nTreg differentiation toward Tr1, an effect potentiated by IFN-α (Fig. 4C1) . Moreover, by enhancing apoptosis of lupus nTregs (Fig. 4 C2 and C3) , IFN-α triggered an accumulation of apoptotic bodies and cell debris, a source of pathogenic autoantigens.
Lupus Activity Associated with C3b and IFN-α. The critical role of C3-derived C3b (measured by serum C3-reduced concentration) and IFN-α in lupus activity was supported by serum analysis of 152 lupus patients. Clinical lupus activity, assessed by SLE Disease Activity Index (SLEDAI) score (26) , strongly correlated with serum C3 levels (r = −0.574; P < 0.001), IFN-α levels (r = 0.652; P < 0.001), and even more with the association in a reverse ranking of C3+IFN-α expressed as (C3+IFN-α) score (r = 0.696; P < 0.001) (Fig. 5 A1-A3) . Moreover, as expected by the effects of complement C3b and IFN-α on IL-10 release by immune cells, SLEDAI score also correlated with serum IL-10 (r = 0.559; P < 0.001) in a score-scale manner (Fig. 5A4) . Dependency of lupus activity on complement C3b, IFN-α, and IL-10 was further strengthened by the comparison of median serum levels of these factors in HD and highly active (SLEDAI score >8), mildly active (SLEDAI score [4] [5] [6] [7] [8] , and inactive (SLEDA score <4) patients (Fig. 5B) .
Discussion
This study establishes that the physiology of nTregs is not predetermined but driven by their microenvironment. Depending on their microenvironment, immune-stimulated nTregs exert either of two distinct regulatory functions, each one displayed by its own suppressive mechanism: (i) under steady state, nTregs silence autoreactive cells by cell-cell contact (self-tolerance), and (ii) during inflammation-induced adaptive immunity, nTregs differentiating to Tr1 down-modulate immune response by releasing IL-10 (adaptive immune regulation) (Table S3 ). Thus, the reported suppressive activity mediated by nTreg-released IL-10 (27) occurring only during inflammation and not under steady state (Fig. 3A3 ) reflects a regulation of adaptive immunity to pathogens and not a cell contact-mediated self-tolerance function. In effect, during adaptive immune reactions triggered by inflammation, immune-stimulated nTregs differentiated to IL-10-secreting Tr1, as did conventional CD4 T cells (Fig. 3 A2 and A3 ). This suggests that Tr1 cells are not a separate T-cell lineage commitment, but represent, during inflammation-triggered adaptive immunity, a stage of functional differentiation in the life cycle of immune-stimulated T cells originating from most, if not all, T-cell subtypes. This paradigm is supported by Tr1 characteristics: (i) their origin from a broad range of Ag-stimulated T cells (8) , (ii) their absence of associated specific phenotypic markers (28) , and (iii) their lack of epigenetic functional memory as assessed by DNA status (29) .
The context-dependent dual regulatory activities of nTregs should highlight the mechanisms triggering their dysfunction in autoimmune diseases. Notably in SLE, complement C3b-induced CD46 stimulation abrogates nTreg control of self-tolerance (Fig.  2A3) , hallmark of autoimmune disorders; instead, CD46 stimulation, synergizing with IFN-α (Fig. 2C) , skews nTregs and Tconv to Tr1 secreting IL-10, which prematurely imbalances the adaptive immunity toward immune suppression. The role of C3b protein, the CD46 agonist resulting from C′ activation, in the pathogenesis of active lupus patients is also suggested by the presence in the serum of these patients of soluble CD46 (30) , product of proteolytic cleavage of apoptotic cell membranes (31) . As for IFN-α, by reducing nTreg and Tconv number and function, this cytokine may further enhance the risk of autoimmunity and infection. This provides a rationale for therapeutically targeting IFN-α to prevent lupus activity (13) . As a proof of concept, we have demonstrated in an IFN-α-dependent lupus model (New Zealand Black × New Zealand White F1 mice), that Ab-induced IFN-α neutralization prevented occurrence of SLE symptoms and death (32) . Finally, considering the context-dependent nTreg functional plasticity therapeutic trials based on adoptive nTregs or cytokines interfering with nTreg physiology, such as IL-2, should be carefully managed to avoid undesirable outcomes as those observed in a recent phase 3 trial in AIDS patients receiving IL-2 (33). Comparison of median serum levels of (B1) C3, (B2) IFN-α, (B3) (C3+IFN-α) score, and (B4) IL-10 in different groups of subjects inactive (IL), midly active (mAL), highly active (hAL) patients, and HD (normal HD serum C3 = 0.9-1.5 g/L). *P < 0.05; **P < 0.005; ***P < 0.001; ns, P > 0.05.
Materials and Methods
Human Subjects. Experiments used blood samples either from healthy individuals (n > 80) obtained through the Etablissement Français du Sang (EFS, Paris) or from lupus patients (n = 152) followed up at Hôpital La Pitié-Salpêtrière (Paris) in the internal medicine department, the French National Reference Center for SLE. Lupus patients consisted of 145 females and 7 males (median age 35 y, range 16-65 y) fulfilling four or more of the American College of Rheumatology classification criteria for SLE (34) . During visits, the SLEDAI was assessed as previously described (26 (Table S2 ). Thirty-nine blood samples collected from age-and sex-matched HDs among those obtained through EFS served as controls. Blood cells and sera were collected using standard procedures. The study was performed according to the Helsinki declaration, and the study protocol was reviewed and approved by the local ethics committee.
Procedures and Methods. Cell separation and culture, flow cytometry, functional assays, including T-cell activation, T-cell proliferation, nTreg cell contact-mediated suppression, IL-10-secreting Tr1 suppression, reversion to the original function of Tr1-differentiated nTregs, cytokines quantification, and real-time PCR analysis of FOXP3 and IL-10 expression are detailed in SI Materials and Methods.
Statistical Analysis. For statistical analysis, we used StatView software. After a preliminary screening, serum C3, IFN-α, and IL-10 more directly linked to SLEDAI score were selected for further analysis by the Mann-Whitney rank sum test (Table S2) . A P value of <0.05 was considered statistically different. Correlations were tested by the Spearman rank correlation, and linear regression analysis was effected; correlations were considered significant at P < 0.05. A (C3+IFN-α) score was calculated for each patient. The SLE patients were divided into three main groups according to their C3 and IFN-α serum levels, respectively, and we assigned to each group a score as follows: patients with a serum C3 level >0.8 g/L were scored as 1, with C3 between 0.7 and 0.8 g/L as 2, and with C3 <0.7 g/L as 3; patients with serum IFN-α level <4 IU/mL were scored as 1, with IFN-α between 4 and 8 IU/mL as 2, and with IFN-α ≥8 IU/mL as 3.
